Clinical Trials Sponsored by Fondazione Italiana Vascolare

Total 167 results

EndoCore Lab s.r.l.
Fondazione Italiana Vascolare

Completed

SUPERa Stenting After SUBintimal Crossing of TASC C-D Femoro-popliteal Lesions in CLI Patients (SUPERSUBII)

PAD

United States, Argentina, Italy, United Kingdom
EndoCore Lab s.r.l.
Fondazione Italiana Vascolare

Recruiting

Shockwave ®S4 Catheter IVL to Treat Infrapopliteal Calcified Stenoses and/or Occlusions in CLTI Patients (LEGACY) (LEGACY)

Peripheral Arterial Disease | Critical Limb-Threatening Ischaemia

Italy
EndoCore Lab s.r.l.
Fondazione Italiana Vascolare

Recruiting

Use of Shockwave M5+ IVL Catheter (Intravascular Lithotripsy) in Hostile and Calcified Iliac Access (SHOCK-ACCESS)

Peripheral Arterial Disease | Aortic Diseases | Aorto-Iliac Atherosclerosis

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto
Fondazione Italiana Linfomi

Recruiting

Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.

COVID-19 | Chronic Lymphocytic Leukemia | Indolent B-Cell Non-Hodgkin Lymphoma

Italy
Fondazione Italiana Linfomi - ETS

Not yet recruiting

Primary Cardiac Lymphoma: Italian Multicenter Experience

Primary Cardiac Lymphoma

Italy
Fondazione Italiana Linfomi - ETS

Recruiting

Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial (FIL_FOLL-BIO)

Follicular Lymphoma

Italy
Fondazione Italiana Linfomi - ETS

Recruiting

Quality Of Life On Elderly Patients With Low Grade Non-Hodgkin Lymphoma

Low Grade Non-Hodgkin's Lymphoma, Adult

Italy
Fondazione Italiana Linfomi ONLUS

Recruiting

Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis

Classical Hodgkin Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Recruiting

Phase II of High-dose Therapy in Elderly Patients With Relapsed Aggressive NHL or Resistant to First Line Therapy

Non Hodgkin Lymphoma

Italy
Fondazione Italiana Sclerosi Multipla

Completed

Pilates Training in Multiple Sclerosis (MS-FIT)

Multiple Sclerosis | Physical Activity

Italy
Fondazione Italiana Linfomi - ETS

Active, not recruiting

Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma

Italy
Fondazione Italiana Linfomi - ETS

Active, not recruiting

Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell

Lymphoma | Large B-Cell | Diffuse Large B-Cell

Italy
Fondazione Italiana Linfomi - ETS

Active, not recruiting

Circulating Tumor DNA Genotyping for Biological Monitoring of Patients Treated in the FIL-Rouge Clinical Trial (FIL-RougeBIO)

Hodgkin Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Completed

A Phase II Study of the FIL on Elderly Frail Patients With DLBCL

Diffuse Large B-cells Non-Hodgkin Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Completed

"MIRO" Molecularly Oriented Immuno-radio-therapy (FIL_MIRO)

Follicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade 3A

Italy
Fondazione Italiana Linfomi ONLUS

Completed

Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL Patients

Lymphatic Diseases

Italy
Fondazione Italiana Linfomi ONLUS

Completed

Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's (FIL_BRB)

Waldenstrom's Macroglobulinemia

Italy
Fondazione Italiana Linfomi ONLUS

Completed

Study on the Role of FDG-PET in Patients With FL at Time of Relapse/Progression

Follicular Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Completed

Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL (R2-B)

Mantle Cell Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Completed

BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in R/R HL Patients Non Responding to IGEV

Relapsed/Refractory Hodgkin's Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Unknown

Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FIL

Diffuse Large B-cell Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Completed

Prognosis of Patients With Relapsed/Refractory Hodgkin Lymphoma Treated With IGEV Induction Therapy Before HDCT With AHSCT (IIL-ProHLRec)

Hodgkin's Lymphoma

Italy
Fondazione Italiana Linfomi - ETS

Not yet recruiting

Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma (FIL_MOGA)

Cutaneous T Cell Lymphoma | Cutaneous T-Cell Lymphoma/Mycosis Fungoides | Cutaneous T-Cell Lymphoma/Sezary Syndrome

Italy
Fondazione Italiana Linfomi - ETS

Not yet recruiting

Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance (FIL_FollVax22)

Follicular Lymphoma

Italy
Fondazione Italiana Linfomi - ETS

Not yet recruiting

Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy (FIL_Tisle-HL)

Hodgkin Lymphoma

Italy
Fondazione Italiana Linfomi - ETS

Recruiting

Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Follicular Lymphoma

Italy
Fondazione Italiana Linfomi - ETS

Active, not recruiting

Non-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM-MGUS (FIL_BIOWM)

Waldenstrom Macroglobulinemia

Italy
Fondazione Italiana Linfomi - ETS

Active, not recruiting

Primary Mediastinal Large B-cell Lymphoma (PMBCL): Multicenter Retrospective Study

Primary Mediastinal Large B-cell Lymphoma (PMBCL)

Italy
Fondazione Italiana Linfomi - ETS

Active, not recruiting

A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)

Relapsed Follicular Lymphoma

Italy
Fondazione Italiana Linfomi - ETS

Terminated

Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma

T-Cell Lymphoma Relapsed | T-Cell Lymphoma Refractory

Italy
Fondazione Italiana Linfomi - ETS

Active, not recruiting

Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas (FIL_PTCL13)

Peripheral T-cell Lymphomas (PTCL) | PTCL-NOS | Angioimmunoblastic T-cell Lymphoma (AITL) | ALK- Anaplastic Large Cell Lymphoma (ALCL) | Nodal Peripheral T-Cell Lymphoma of T Follicular Helper Cell Origin

Italy
Fondazione Italiana Linfomi - ETS

Active, not recruiting

Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients (FIL_RENOIR12)

Lymphoma, Follicular

Italy
Fondazione Italiana Linfomi ONLUS

Completed

R-CHOP14 or R-CHOP21 &Consolidation PET-Oriented Radiotherapy (RT) in DLBCL Patients (FIL_DLCL10)

Diffuse Large B Cell Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Completed

Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas

Aggressive Non-Hodgkin Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Terminated

GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma (FIL_GAEL)

CD20 Positive Diffuse Large B-cell Lymphoma | Elderly Unfit Patients

Italy
Fondazione Italiana Linfomi ONLUS

Completed

Oral Panobinostat Adult Patients DLBCL Relapsed/Refractory Stem Cell Transfusion (ASCT) or Not Eligible for ASCT (FIL_PanAL10)

Diffuse Large B-cell Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Completed

Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients (FIL_GEMRO)

Peripheral T-cell Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Completed

A Phase II Study for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma (IIL INFL09)

Non-Hodgkin's Lymphoma | Indolent Non-follicular

Italy
Fondazione Italiana Linfomi ONLUS

Completed

A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL (FIL_SGN01)

Primary Mediastinal Large B Cell Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Terminated

Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients. (FIL-GALILEO)

Lymphoma, B-Cell

Italy
Fondazione Italiana Linfomi - ETS

Not yet recruiting

Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors

Classical Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Diffuse Large B Cell Lymphoma (DLBCL)

Italy
Fondazione Italiana Linfomi - ETS

Recruiting

Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients. (FIL_COLUMN)

Refractory Mantle Cell Lymphoma | Relapsed Mantle Cell Lymphoma

Italy
Fondazione Italiana Linfomi - ETS

Recruiting

Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.

Mantle Cell Lymphoma

Italy
Fondazione Italiana Linfomi - ETS

Active, not recruiting

The Role of 18F-FDG-PET for Staging and Prognostication

Mantle Cell Lymphoma

Portugal, Italy
Fondazione Italiana Linfomi - ETS

Active, not recruiting

FIL Study on ABVD DD-DI as Upfront Therapy in HL.

Hodgkin Lymphoma

Italy
Fondazione Italiana Linfomi - ETS

Active, not recruiting

Indolent Non Follicular Lymphomas Prognostic Project

Indolent B-Cell Lymphomas

France, Italy, Brazil, Austria, Portugal, Ukraine
Fondazione Italiana Linfomi - ETS

Terminated

Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma (GAUDEALIS)

Follicular Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Completed

Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection

Hepatitis C | Indolent B-cell Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Active, not recruiting

Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL (FIL_KLIMT)

Mantle Cell Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Completed

Phase II Study of Age-Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With MCL (FIL-RBAC500)

Mantle Cell Lymphoma

Italy

3

Subscribe